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We examined the in vivo effects of the hallucinogen 4-iodo-2,5-
dimethoxyamphetamine (DOI). DOI suppressed the firing rate of
7 of 12 dorsal raphe (DR) serotonergic (5-HT) neurons and
partially inhibited the rest (ED50  20 g/kg, i.v.), an effect
reversed by M100907 (5-HT2A antagonist) and picrotoxinin
(GABAA antagonist). DOI (1 mg/kg, s.c.) reduced the 5-HT
release in medial prefrontal cortex (mPFC) to 33  8% of
baseline, an effect also antagonized by M100907. However, the
local application of DOI in the mPFC increased 5-HT release
(164  6% at 100 M), an effect antagonized by tetrodotoxin,
M100907, and BAY  3702 (5-HT1A agonist) but not by SB
242084 (5-HT2C antagonist). The 5-HT increase was also re-
versed by NBQX (AMPA–KA antagonist) and 1S,3S-ACPD
(mGluR 2/3 agonist) but not by MK-801 (NMDA antagonist).
AMPA mimicked the 5-HT elevation produced by DOI. Likewise,
the electrical–chemical stimulation of thalamocortical afferents
and the local inhibition of glutamate uptake increased the 5-HT
release through AMPA receptors. DOI application in mPFC
increased the firing rate of a subgroup of 5-HT neurons (5 of 10),
indicating an enhanced output of pyramidal neurons. Dual-label
fluorescence confocal microscopic studies demonstrated co-
localization of 5-HT1A and 5-HT2A receptors on individual cor-
tical pyramidal neurons.
Thus, DOI reduces the activity of ascending 5-HT neurons
through a DR-based action and enhances serotonergic and
glutamatergic transmission in mPFC through 5-HT2A and AMPA
receptors. Because pyramidal neurons coexpress 5-HT1A and
5-HT2A receptors, DOI disrupts the balance between excitatory
and inhibitory inputs and leads to an increased activity that may
mediate its hallucinogenic action.
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The prefrontal cortex plays a crucial role in higher brain functions
(Fuster, 1997). It receives a dense innervation from the brainstem
aminergic nuclei, including the serotonergic dorsal and median
raphe nuclei of the midbrain (Azmitia and Segal, 1978). The
prefrontal cortex contains a very large density of 5-HT1A and
5-HT2A receptors located on pyramidal neurons. Likewise,
GABAergic interneurons are enriched in 5-HT2A and 5-HT3
receptors (Pompeiano et al., 1992, 1994; Kia et al., 1996; Willins
et al., 1997; Jakab and Goldman-Rakic, 1998, 2000). Although the
exact role of serotonergic neurotransmission in prefrontal cortex
remains largely unknown (Robbins, 2000) serotonergic agents
acting on cortical receptors are hallucinogenic [nonselective
5-HT2A agonists such as D-lysergic acid diethylamide-25 (LSD) or
4-iodo-2,5-dimethoxyamphetamine (DOI)] or have proven effec-
tive in the treatment of depression and schizophrenia (5-HT
uptake inhibitors, 5-HT1A agonists/5-HT2A antagonists) (Kroeze
and Roth, 1998; Meltzer, 1999).
5-HT exerts complex actions on pyramidal neurons of the
medial prefrontal cortex (mPFC). Previous work showed that
5-HT hyperpolarizes and depolarizes layer V pyramidal neurons
by acting on 5-HT1A and 5-HT2 receptors, respectively (Araneda
and Andrade, 1991), although no direct anatomical evidence for
the colocalization of both receptors on individual pyramidal
neurons has thus far been presented. More recently, Aghajanian
and Marek (1997) demonstrated that the focal application of
5-HT on apical dendrites of pyramidal neurons in the mPFC
evoked EPSCs by a 5-HT2A receptor-dependent mechanism.
Likewise, the hallucinogen DOI, a partial 5-HT2A/2C receptor
agonist, enhanced late EPSCs evoked by the electrical stimula-
tion of afferent fibers (Aghajanian and Marek, 1999a). These
effects are most likely mediated by a release of glutamate, triggered
by the activation of 5-HT2A receptors, and the subsequent activa-
tion of AMPA receptors (Aghajanian and Marek, 1997, 1999a,b).
The apparent presence of 5-HT1A and 5-HT2A receptors in
layer V pyramidal neurons suggests that they could be involved in
the control of subcortical structures. The mPFC is one of the few
forebrain areas projecting densely to the serotonergic dorsal
raphe nucleus (DR) (Aghajanian and Wang, 1977; Sesack et al.,
1989; Hajo´s et al., 1998; Peyron et al., 1998). Additionally, the
electrical stimulation of the mPFC modulates the activity of 5-HT
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neurons in a complex manner (Hajo´s et al., 1998; Celada et al.,
2001). Moreover, the activation of postsynaptic 5-HT1A receptors
in the mPFC reduced the local release of 5-HT (Casanovas et al.,
1999) and the firing rate of dorsal raphe 5-HT neurons (Celada et
al., 2001). These data suggest that pyramidal neurons containing
5-HT1A receptors may participate in the distal control of seroto-
nergic activity. Because 5-HT1A and 5-HT2A receptors may co-
localize in layer V pyramidal neurons projecting to the DR,
5-HT2A receptors could be involved in this control. Therefore, in
the present study we examined the actions of the hallucinogen
DOI, a 5-HT2A/2C agonist, on the serotonergic system using in
vivo microdialysis and single-unit recordings. The results obtained
indicate that 5-HT2A receptor activation has profound effects on
serotonergic neurons, likely via an enhancement of the AMPA-
mediated neurotransmission in medial prefrontal cortex.
MATERIALS AND METHODS
Animals. Male albino Wistar rats (Iffa Credo, Lyon, France) weighing
280–320 gm and kept in a controlled environment (12 hr light /dark cycle
and 22  2°C room temperature) with food and water provided ad
libitum, were used in in vivo experiments. Animal care followed the
European Union regulations (O.J. of E.C. L358/1 18/12/1986).
Drugs and reagents. 5-HT oxalate, 8-hydroxy-2-(di-n-propylamino)tetralin
(8-OH-DPAT),-amino-3-hydroxy-5-methyli-4-soxazole-4-propionate[(S)-
AMPA],bicuculline,cyclothiazide,1-[2,5-dimethoxy-4-iodophenyl-2-amino-
propane (DOI), L-trans-pyrrolidine-2,4-dicarboxylic acid (L-trans-PDC),
()MK-801 (dizolcipine), NBQX, 2,3-dihydroxy-6-nitro-7-sulfamoyl-
benzo(f)quinoxaline, picrotoxininin, 6-chloro-5-methyl-1-[6-(2-methylpy-
ridin-3-yloxy) pyridin-3-yl carbamoyl] indoline (SB 242084), tetrodotoxin
(TTX), and N-(2-(4-(2-methoxyphenyl)-1-piperazinyl)ethyl)-N-(2-pyridyl)
cyclohexanecarboxamide  3HCl (WAY-100635), were from Sigma/Re-
search Biochemicals (Natick, MA). 1S,3S-aminecyclopentane dicarboxylic
acid (1S,3S-ACPD) was from Tocris (Bristol, UK). BAY  3702, {R-(-)-
2–237 4-[(chroman-2-ylmethyl)-amino]-butyl 253–1,1-dioxo-benzo[d]
isothiazolone  HCl}, citalopram  HBr, LY 379268 {()-2-oxa-4-amino-
bicyclo[3.1.0]hexane-4,6-dicarboxylate]}, and M100907 [R-()--(2,3-dime-
thoxyphenil)-1-[4-fluorophenylethyl]-4-piperidinemethanol] were from
Bayer AG, Lundbeck A/S, Eli Lilly & Co. (Indianapolis, IN), and Marion
Merrel Dow (Strasbourg, France), respectively. A mouse monoclonal
5-HT2A antibody and a guinea pig polyclonal 5-HT1A antibody were ob-
tained from PharMingen (San Diego, CA). Other materials and reagents
were from local commercial sources. For the assessment of local effects,
drugs were dissolved in the perfusion fluid and applied by reverse dialysis
at the stated concentrations. Concentrated solutions (1 mM; pH adjusted to
6.5–7 with NaHCO3 when necessary) were stored frozen (80°C), and
working solutions were prepared daily by dilution. Concentrations are
expressed as free bases. Control rats were perfused for the entire experi-
ment with artificial CSF. The bars in the figures show the period of drug
application (corrected for the void volume of the system). In experiments
involving systemic administration, the drugs were administered subcutane-
ously or intravenously at the doses stated.
Surgery and microdialysis procedures. An updated description of the
microdialysis procedures used can be found in Adell and Artigas (1998).
Briefly, anesthetized rats (pentobarbital; 60 mg/kg, i.p.) were stereotaxi-
cally implanted with one concentric microdialysis probe equipped with a
Cuprophan membrane in medial prefrontal cortex [anteroposterior (AP)
3.4, lateral (L) 0.8, dorsoventral (DV) 6.0; probe tip: 4 mm] (coor-
dinates in millimeters; Paxinos and Watson, 1986). On the next day,
microdialysis experiments were performed in freely moving rats. The
probes were perfused at 1.5 l /min with artificial CSF (aCSF) (in mM:
125 NaCl, 2.5 KCl, 1.26 CaCl2, and 1.18 MgCl2) containing 1 M
citalopram. After a 1 hr stabilization period, four fractions were collected
to obtain basal values before local (reverse dialysis) or systemic admin-
istration of drugs. Successive 20 min (30 l) dialysate samples were
collected. In most experiments, the partial 5-HT2A/2C receptor agonist
DOI was applied alone for 2 hr (six fractions). This was followed by the
application of DOI in combination with other drugs for another 2 hr
period. In experiments assessing the effect of L-trans-PDC on 5-HT
release, the drug was perfused alone or in combination with other agents
for 2 hr after collection of baseline values.
Three microdialysis experiments were conducted in chloral hydrate-
anesthetized animals. In one of them, we examined the effect of the
electrical stimulation of the midline thalamus projecting to mPFC, to
modulate the release of 5-HT in the latter area. Microdialysis probes
were implanted as above. Stimulating bipolar electrodes were used. The
isolating material was peeled off 1 mm above the tip, the poles were
separated 100–150 m, and electrodes were stereotaxically placed and
secured with dental cement, as for microdialysis probes. The tip of the
electrodes was aimed at the top part of the centromedial thalamic nucleus
(AP 3.6, L 0.7, DV 6.5). In this manner, the stimulated area was
between DV 6.5 and DV 5.5, thus affecting the mediodorsal nucleus
and part of the centromedial nucleus (plate 32; Paxinos and Watson,
1986). The lesion of this thalamic area has been shown to attenuate the
EPSCs induced by 5-HT in layer V mPFC pyramidal neurons (Marek et
al., 2001). On the next day, rats were anesthetized with chloral hydrate as
in single-unit recording experiments (see below). After a 2 hr stabiliza-
tion period, electrical stimulation was performed (5 Hz, 1.5 mA, 0.3 msec
square pulses) for 20 min with a Grass S-48 stimulator unit S-48 con-
nected to a Grass SIU isolation unit, and dialysate fractions were col-
lected for one more hour. In some rats, the stimulating electrode was
implanted, but no current was passed.
The second experiment examined the effects of the application of
bicuculline in the midline thalamus (to disinhibit afferent fibers to
mPFC) on the 5-HT release in mPFC. These rats were implanted with
two dialysis probes, in mPFC (as above) and in the thalamus (coordi-
nates: AP 3.2, L 0.5, DV 6.5; probe tip, 1.5 mm). In this location,
the administration of bicuculline by reverse dialysis through the thalamic
probe was also intended to affect both the centromedial and mediodorsal
thalamic nuclei. The third experiment assessed the effects of the systemic
administration of DOI (1 mg/kg, s.c.) on 5-HT release in the mPFC of
chloral hydrate-anesthetized rats, to mimic the experimental conditions
of single-unit recordings. At the end of the experiments, rats were killed
by an overdose of sodium pentobarbital. The placement of the dialysis
probes was examined by perfusion of Fast green dye and visual inspec-
tion of the probe track after cutting the brain at the appropriate levels. In
experiments involving the electrical or chemical stimulation of thalamic
afferents to mPFC, the placement of the thalamic probes or electrodes
was verified histologically with Neutral Red staining.
The concentration of 5-HT in dialysate samples was determined by
HPLC, as described (Adell and Artigas, 1998). 5-HT was separated using
a Beckman (San Ramon, CA) 3 m particle size column and detected
with a Hewlett Packard 1049 electrochemical detector at 0.6 V. Reten-
tion time was between 3.5 and 4 min, and the limit of detection was
typically 1 fmol /sample.
Single-unit recordings. We examined the effect of the systemic admin-
istration of DOI on the firing activity of identified 5-HT neurons in the
dorsal raphe nucleus (DR). Single-unit extracellular recordings were
performed as previously described (Sawyer et al., 1985; Celada et al.,
1996). Briefly, rats were anesthetized (chloral hydrate, 400 mg/kg, i.p.)
and positioned in a stereotaxic apparatus. Additional doses of chloral
hydrate (80 mg/kg) were administered intravenously. Body temperature
was maintained at 37°C throughout the experiment with a heating pad.
All wound margins and points of contact between the animal and the
stereotaxic apparatus were infiltrated with lidocaine solution (5%). To
minimize pulsation, the atlanto-occipital membrane was punctured to
release some CSF. For recordings in the DR, a burr hole of 4  4 mm
was drilled over lambda, and the sagittal sinus was ligated, cut, and
reflected. Single units in the DR were recorded extracellularly with glass
micropipettes pulled from 2.0 mm capillary glass (World Precision In-
struments, Sarasota, FL) on a Narishige (Tokyo, Japan) PE-2 pipette
puller. Microelectrodes were filled with 2 M NaCl. Typically, impedance
was between 4 and 10 M. Descents were performed along the midline.
Recorded 5-HT neurons were found 5.0–5.8 mm below the brain surface
and were identified according to previously described electrophysiologi-
cal criteria (Wang and Aghajanian, 1977). They exhibited a regular
spontaneous firing rate with frequencies from 0.4 to 2.2 Hz, and 2–5 msec
biphasic or triphasic extracellular waveform.
Single-unit potentials were amplified with a Neurodata IR283 (Cygnus
Technology Inc., Delaware Water Gap, PA), postamplified, and filtered
with a Cibertec amplifier (Madrid, Spain) and computed on-line using a
DAT 1401plus interface system Spike2 software (Cambridge Electronic
Design, Cambridge, UK). After recording stable baseline spontaneous
activity for at least 5 min, DOI was administered (0.025–0.4 mg/kg, i.v.;
cumulative doses) every 2 min. Once a maximal effect of DOI was
attained, either M100907 (100 g/kg, i.v.; Haddjeri et al., 1999) or the
GABAA receptor antagonist picrotoxinin (1 mg/kg, i.v.) were injected. In
some neurons, 8-OH-DPAT and WAY 100635, 5-HT1A receptor agonist
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and antagonist, respectively, were injected after M100907 or picrotoxinin
to further confirm the serotonergic identity of the recorded cell. Only
one neuron per rat was recorded.
Additional experiments were performed to examine the effects of the
local application of DOI in mPFC on the firing rate of 5-HT neurons in
the DR. DOI (200 M, dissolved in aCSF) was infused through a 32
gauge stainless steel cannula (Small Parts Inc., Miami, FL) implanted in
the mPFC (tip coordinates: AP 3.4, L 0.8, DV 4.5). The cannula
was attached to a 10 l Hamilton syringe by a Teflon tubing. A micro-
infusion pump (Bioanalytical Systems Inc., West Lafayette, IN) was
used. After recording baseline spontaneous activity for at least 5 min, 200
nl of DOI was infused over the course of 1 min. This volume has been
reported to diffuse to a maximum effective diameter of 0.4–0.6 mm
(Myers, 1971). In some rats, a second DOI infusion was administered 5
min later.
Data and statistical analysis. Microdialysis results are expressed as
femtomoles per fraction (uncorrected for recovery) and shown in figures
as percentages of basal values (individual means of four predrug frac-
tions). Statistical analysis of drug effects on dialysate 5-HT was per-
formed using one- or two-way ANOVA for repeated measures of raw
data with time as repeated factor and dose or pretreatment as indepen-
dent factor. The effects of drugs or chemical stimulation on the 5-HT
output were analyzed by one- or two-way ANOVA of raw data followed
by post hoc Duncan test. Changes in firing rate were quantified by
averaging the values in the second minute after drug injection and
expressed as percentage of baseline. ED50 values were calculated with the
GraphPad (San Diego, CA) Prism program. Data are expressed as the
mean  SEM. Statistical significance has been set at the 95% confidence
level (two-tailed).
Cell culture and monoclonal antibody production. Stably transfected
Chinese Hamster Ovary (CHO) cells expressing the 5-HT1A receptor
were obtained from J. Raymond (Medical University of South Carolina,
Charleston, SC). A monoclonal 5-HT1A receptor antibody was prepared
as follows. Female BALB/c mice were immunized intraperitoneally with
50 g of a synthetic peptide (NKRTPRRAAALISLC) conjugated to
Limulus polyphemus hemocyanin and emulsified in Freund’s adjuvant.
Immune spleens were harvested after 3 months and fused with SP2/0
myeloma cells at a ratio of four spleen cells per myeloma using phenyl-
ethyleneglycol. Antibody-producing colonies were detected by ELISA as
follows: immunizing peptide conjugated to BSA (10 g/ml) was immo-
bilized to COSTAR 9017 EIA/RIA plates in 100 l of coating buffer (50
mM carbonate–bicarbonate, pH 9.6) and incubated overnight at room
temperature. Wells were blocked with 2% milk in PBS (blocking buffer)
1 hr, followed by addition of antibody in culture supernatant or in
blocking buffer for 90 min. Antibodies were detected using a horse
anti-mouse polyclonal antibody linked to horseradish peroxidase (Vector
Laboratories, Burlingame, CA; 1:2000 in blocking buffer) followed by
spectrophotometric detection at 405 nm using the 2,2-azino-bis(3-
ethylbenzthiazoline-6-sulfonic acid) substrate system (Sigma, St. Louis,
MO). Hybridomas were subjected to three rounds of limiting dilution
cloning, after which antibody was produced in bulk by generation of
ascites in histocompatible mice. Immunoreactivity of the antibodies was
confirmed both by ELISA (as described above) and by immunohisto-
chemical staining using CHO cells (control) or CHO cells stably express-
ing the 5-HT1A receptor. Briefly, cells on microscope coverslips in 24 well
microtiter plates were serum-starved overnight at 37°C and 5% CO2,
then fixed in 4% paraformaldehyde and maintained at room tempera-
ture. Cells were permeabilized 20 min with 0.1% Triton X-100 and
blocked with 2% milk for 1 hr. Anti-5-HT1A antibody supernatants were
incubated with the cells for 90 min, followed by incubation for 1 hr with
a Texas Red-labeled goat anti-mouse secondary reagent (Vector Labo-
ratories). Cells were then mounted for confocal microscopy as previously
described (Willins et al., 1997, 1999).
Confocal immunofluorescence studies. Rats were prepared for immu-
nofluorescence studies as previously detailed (Willins et al., 1997, 1999),
and free-floating 40 m sections of mPFC were prepared as described
previously (Willins et al., 1997, 1999). Free-floating sections were then
incubated in blocking buffer (PBS containing 0.2% Triton X-100, 5%
nonfat dry milk, and 1% goat serum) for 1 hr at room temperature.
Sections were then incubated for 1 hr at room temperature with a 1:3000
dilution of polyclonal 5-HT2A-selective antibody (Berry et al., 1996) and
a 1:10 dilution of a monoclonal 5-HT1A antibody in blocking buffer.
Additional sections were incubated with a commercial monoclonal
5-HT2A receptor antibody (1:500; PharMingen) and a commercial guinea
pig polyclonal 5-HT1A receptor antibody (1:2000; PharMingen). Sections
were then incubated overnight at 4°C with constant agitation. After
extensive washing with PBS, sections were incubated with a 1:200 dilu-
tion of secondary antibodies (BODIPY-FL-anti-mouse and Texas Red
anti-rabbit or Texas Red anti-guinea pig) for 1 hr at room temperature
followed by extensive washing with PBS and mounting for confocal
microscopy as previously detailed (Willins et al., 1997, 1999). Controls
included incubation of sections with secondary antibody alone.
Dual-label confocal microscopy was performed using a Zeiss Model
410 confocal microscope as previously described (Willins et al., 1997,
1999), and images were processed using Adobe Photoshop.
RESULTS
Baseline 5-HT values
The basal concentration of 5-HT in dialysates from medial pre-
frontal cortex was 17.5  0.8 fmol/fraction (n  105) in freely
moving rats and 17.0  1.1 fmol/fraction (n  24) in chloral
hydrate-anesthetized rats.
Effects of the local application of DOI in medial
prefrontal cortex
The local application of 1, 10, and 100 M DOI (2 hr each)
increased the 5-HT output in a concentration-dependent manner.
Maximal increases at each concentration were, respectively 119
20, 137  16, and 209  29% of baseline (n  5) (Fig. 1A).
One-way ANOVA showed a significant effect of DOI application
( p 	 0.00001). In subsequent experiments, we used the concen-
tration of DOI that elicited maximal effects (100 M).
Figure 1. A, Concentration-dependent increase of 5-HT in dialysates
from medial prefrontal cortex evoked by the local application of 1, 10, and
100 M of the partial 5-HT2A/2C receptor agonist DOI ( filled circles; n 
5). The bar graph in the inset shows the average increase in 5-HT obtained
from the last four (stabilized) fractions at each DOI concentration (p 	
0.05 vs baseline). B, Effect of the continuous application of 100 M DOI
( filled squares; n  7). Control rats (n  6) received artificial CSF
throughout the experiment. Bars show the period of drug application.
p 	 0.05 versus baseline; Duncan test post-ANOVA.
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The perfusion of 100 M DOI (n 7) significantly increased the
5-HT output when compared with the control group (artificial
CSF; n  7) ( p 	 0.02, treatment effect; p 	 0.00001, time effect;
p 	 0.00001 time  treatment interaction) (Fig. 1B). Maximally
elevated 5-HT values were observed soon (40 min) after DOI
application and remained elevated over the entire period of
application. The mean increase produced by 100 M DOI in all
perfusion experiments was 164  6% of baseline (average of
fractions 7–10; n  69).
The effect of DOI was completely antagonized by the coper-
fusion of 1 M TTX, which reduced 5-HT values below baseline
(from 185  10 to 30  6% of baseline; n  4; p 	 0.00001) (Fig.
2). Likewise, the 5-HT increase produced by 100 M DOI was
significantly attenuated by the coperfusion of 100 M of the
selective 5-HT2A receptor antagonist M100907 (DOI: 181  8%
of baseline; DOI  M100907: 119  13% of baseline; n  8; p 	
0.00001) (Fig. 3A). A higher M100907 concentration (300 M)
elicited a greater reduction of the 5-HT output (from 163  1%
to 42 6% of baseline, n 6; p	 0.00001) (Fig. 3A). In contrast,
the selective 5-HT2C receptor antagonist SB 242084 did not
reverse the 5-HT elevation produced by DOI and increased the
5-HT output further, from 178  22% to 224  25% of baseline
(n  6; p 	 0.00001) (Fig. 3B).
The perfusion of the noncompetitive NMDA receptor antag-
onist MK-801 (300 M) did not significantly modify the effect of
DOI (n  7) (Fig. 4A). In contrast, the application of the AM-
PA–KA receptor antagonist NBQX (300 M) significantly re-
duced the effect of DOI (from 182  15% to 122  13% of
baseline; n  6; p 	 0.00001) (Fig. 4B). The perfusion of the
preferential mGluR 2/3 agonist 1S,3S-ACPD (300 M) modestly
reversed the effect of DOI on 5-HT output only in the last two
fractions (n  5; p 	 0.00001) (Fig. 4C). A higher concentration
of 1S,3S-ACPD (1 mM) elicited a more marked antagonism and
almost completely reversed the effect of DOI, from 190  15 to
112  6% of baseline (n  5; p 	 0.00001) (Fig. 4C). In contrast,
the application of the selective mGluR 2/3 agonist LY 379268,
perfused at three different concentrations (300 M, 1 mM, and 3
mM) failed to significantly reduce the 5-HT increase induced by
the local application of DOI. The average effect of LY 379268 was
96  16, 97  12, and 107  10% at 300 M, 1 mM, and 3 mM,
respectively (n  4–5, data expressed as percentage of the 5-HT
values during DOI alone). The effect of DOI was mimicked by the
local application of AMPA (300 M), which induced a maximal
elevation of 5-HT to 188 15% of baseline ( p	 0.001, treatment
effect; p 	 0.00001, time effect; p 	 0.00001, time  treatment
interaction compared with controls; n  6) (Fig. 4D).
The increase in 5-HT output produced by the application of
DOI was strongly antagonized by the coperfusion of the selective
5-HT1A receptor agonist BAY  3702 (De Vry et al., 1998;
Casanovas et al., 2000) (30 M; from 189  30 to 60  13% of
baseline; n  5; p 	 0.00001) (Fig. 5).
Localization of 5-HT1A and 5-HT2A receptors on
individual mPFC pyramidal neurons
The opposite effects of 5-HT1A and 5-HT2A receptor activation in
mPFC on 5-HT release are in keeping with previous data on
pyramidal neuron excitability (Araneda and Andrade, 1991).
However, despite abundant literature on the localization of either
type in cortical neurons (see introductory remarks), it is unclear
whether both receptors are coexpressed in pyramidal neurons. To
address this question, we prepared a monoclonal 5-HT1A recep-
tor antibody suitable for immunochemical studies. In preliminary
studies (D. A. Shapiro and B. L. Roth, unpublished observations)
we observed that the monoclonal 5-HT1A receptor antibody spe-
cifically labeled 5-HT1A receptors stably expressed in CHO cells
but did not visualize untransfected CHO cells. As shown in
Figure 2. The perfusion of tetrodotoxin (TTX; 1 M) reversed the
increase in 5-HT output induced by the local application of DOI 100 M
(n 4). Bars show the period of drug application. The effect of DOI alone
is shown by a dotted line. p	 0.05 versus baseline (DOI alone); *p	 0.05
versus DOI alone (DOI  drug); Duncan test post-ANOVA.
Figure 3. A, The application of the selective 5-HT2A receptor antagonist
M100907 (100 and 300 M; filled triangles and circles, n  8 and 4,
respectively) antagonized the increase in 5-HT output induced by the
local application of DOI 100 M. B, Lack of antagonism of the effect of
DOI by the selective 5-HT2C receptor antagonist SB 242084 (100 M; filled
circles, n 6). This drug significantly potentiated the 5-HT increase elicited
by DOI (shown by a dotted line). p 	 0.05 versus baseline (DOI alone);
*p 	 0.05 versus DOI alone (DOI  drug); Duncan test post-ANOVA.
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Figure 6A–F, 5-HT1A and 5-HT2A receptors were abundantly
colocalized on individual mPFC pyramidal neurons. Control ex-
periments using secondary antibodies alone showed no specific
immunofluorescence (Fig. 6 I). Additional studies using commer-
cially available antibodies directed against distinct epitopes of the
5-HT1A and 5-HT2A receptors (Fig. 6G,H) also showed extensive
colocalization of 5-HT1A and 5-HT2A receptors in individual
cortical pyramidal neurons.
Effects of increased glutamatergic transmission in
mPFC on serotonergic function
The above microdialysis results suggested that DOI increased
5-HT release in mPFC indirectly, possibly by (1) enhancing a
glutamatergic tone on 5-HT nerve terminals (local effect) and/or
(2) by enhancing the activity of ascending 5-HT neurons in the
DR through descending excitatory inputs. We therefore exam-
ined the effects of directly increasing the glutamatergic activity in
mPFC on the local 5-HT release.
We first studied whether the 5-HT-increasing effects of DOI
could be mimicked by endogenous glutamate. To this end, we
electrically stimulated the mediodorsal and centromedial tha-
lamic nuclei (5 Hz, 1.5 mA, 0.3 msec) for 20 min and collected
dialysate fractions from the ipsilateral mPFC. The electrical stim-
ulation of these nuclei elevated the 5-HT output in mPFC to a
maximum of 179  31% of baseline ( p 	 0.00001; n  6) (Fig.
7A). Sham stimulation did not alter 5-HT levels (n 6) (Fig. 7A).
Likewise, in dual probe microdialysis experiments, the applica-
tion of bicuculline (300 M and 1 mM) by reverse dialysis in the
mediodorsal and centromedial thalamic nuclei doubled the 5-HT
release in mPFC (n  8; p 	 0.0007) (Fig. 7B).
Moreover, the local (in mPFC) application of the glutamate
uptake inhibitor L-trans-PDC markedly increased the local 5-HT
release (n  4; p 	 0.000001) (Fig. 7C). The time course of the
Figure 4. A, The application of the noncompetitive NMDA receptor antagonist MK-801 (300 M) did not reverse the increase in 5-HT output induced
by DOI 100 M (n  7). B, Antagonism by the AMPA–KA antagonist NBQX (300 M) of the effect of DOI (n  7). C, The mGluR 2/3 agonist
1S,3S-ACPD (300 M, filled triangles; 1 mM, filled circles; n  5 each) reversed the 5-HT elevation induced by DOI. D, The perfusion of 300 M AMPA
elevated the 5-HT similarly to DOI (n  6; filled circles). The effect of DOI alone is shown by a dotted line. p 	 0.05 versus baseline (DOI or AMPA);
*p 	 0.05 versus DOI alone (DOI  drug); Duncan test post-ANOVA.
Figure 5. The selective 5-HT1A receptor agonist BAY  3702 (30 M)
reversed the DOI-induced increase in 5-HT output (n  5). The effect of
DOI alone is shown by a dotted line. p	 0.05 versus baseline (DOI alone);
*p 	 0.05 versus DOI alone (DOI  drug); Duncan test post-ANOVA.
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effect differed from that elicited by AMPA (Fig. 4D) and showed
a marked tachyphylaxis. However, the 5-HT increase was fully
prevented by the coapplication of 300 M NBQX ( p	 0.00005 vs
L-trans-PDC alone) (Fig. 7C) but not by 300 M MK-801, thus
supporting the involvement of AMPA–KA receptors. The coap-
plication of 300 M cyclothiazide to prevent a putative desensiti-
zation of the glutamate receptors involved in this effect failed to
modify the effect of L-trans-PDC, suggesting that the transient
nature of the 5-HT increase was likely attributable to presynaptic
adaptive mechanisms after glutamate uptake blockade.
Effects of DOI on the firing rate of 5-HT neurons in
the DR
The systemic administration of DOI to chloral hydrate-
anesthetized rats induced a dose-dependent reduction of the
firing rate of 5-HT neurons in the DR (Fig. 8). Two putative
subgroups of neurons were identified, according to the maximal
effect of DOI. In 7 of 12 neurons recorded, DOI fully suppressed
the serotonergic activity at low doses. In the rest (n  5), the
effect of DOI on serotonergic cell firing was partial, with a
Figure 6. Colocalization of 5-HT2A and 5-HT1A receptors in individual cortical neurons. A shows a representative mPFC section depicting individual
cortical neurons expressing 5-HT1A-like immunoreactivity; B shows the same section with 5-HT2A-like immunoreactivity; C depicts an overlay showing
colocalization of 5-HT2A and 5-HT1A receptor-like immunoreactivity in individual cortical neurons. Magnification, 400. D shows a high-power (1000)
view of individual cortical neurons expressing 5-HT1A-like immunoreactivity; E shows the same section with 5-HT2A-like immunoreactivity; F depicts
an overlay of 5-HT1A and 5-HT2Alike immunoreactivity. G shows a low-power (400) view of cortical neurons visualized with a guinea pig 5-HT1A
receptor antibody, whereas H shows the same section visualized with a monoclonal 5-HT2A receptor antibody, with colocalization indicated by
arrowheads. I shows a typical section incubated only with secondary antibodies (400).
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maximal decrease to 40% of baseline. The administration of
additional doses of DOI did not result in a further reduction. In
some neurons, higher doses of DOI appeared to elicit a slight
increase in firing rate, as shown in Figure 8B. In both subgroups,
the effect of DOI was reversed by the administration of M100907
(100 g/kg, i.v.) (Fig. 8B,D). The calculated ED50 value was 20
g/kg intravenously for all neurons (19 and 22 g/kg, i.v., for
neurons with full and partial inhibitory response, respectively).
When examined, the administration of the 5-HT1A receptor ag-
onist 8-OH-DPAT suppressed serotonergic cell firing in both
subgroups of neurons (Fig. 8C,D). The further administration of
WAY 100635 (10 g/kg, i.v.) returned firing rate to baseline (Fig.
8D). The inhibitory effect of DOI on serotonergic cell firing was
also reversed by the administration of the GABAA receptor
antagonist picrotoxinin (1 mg/kg, i.v.) (Fig. 8E).
To assess whether the increased mPFC release of 5-HT in-
duced by local DOI application was caused by the activation of
pyramidal neurons projecting to the DR (thus enhancing the
activity of ascending 5-HT neurons), we locally infused DOI in
the mPFC while recording 5-HT neurons in the DR. In 5 of 10
serotonergic neurons in the DR, the application of DOI in mPFC
(200 M, 200 nl applied in 1 min) enhanced their firing rate (to
194  45% of baseline; range, 137–371%; p 	 0.02) (Fig. 9A).
One additional neuron had a marginal increase (115% of base-
line), and the rest were unaffected by the application of DOI in
mPFC (Fig. 9B). The effects of a second dose of DOI (5 min after
the first one) were examined in seven neurons. Of these, three
responded with a further increase in DR firing (from 155 to 260%
of baseline). The infusion of vehicle in mPFC did not affect the
firing rate of DR 5-HT neurons (data not shown).
Effect of the systemic administration of DOI on 5-HT
release in medial prefrontal cortex
The systemic administration of DOI (1 mg/kg, s.c.) to chloral
hydrate-anesthetized rats reduced the extracellular 5-HT concen-
tration in the mPFC to a maximal effect of 33  8% of baseline
2 hr after administration (n 4; p	 0.00001) (Fig. 10). The effect
of DOI was reversed by the administration of M100907 (0.5
mg/kg, s.c.) which returned 5-HT levels to above baseline (127 
6%; p 	 0.00001) (Fig. 10).
DISCUSSION
The present results show that the stimulation of 5-HT2A receptors
by the hallucinogen DOI markedly affects serotonergic transmis-
sion. Systemic DOI administration reduced the activity of DR
5-HT neurons and their release by mPFC terminals. Conversely,
the selective activation of prefrontal 5-HT2A receptors raised the
local 5-HT release and the firing of a subgroup of 5-HT neurons.
Despite the low density of 5-HT2A receptors in the DR and
adjacent areas (Pompeiano et al., 1994; Fay and Kubin, 2000),
bath application of 5-HT and DOI increased a 5-HT2A receptor-
dependent GABA input onto 5-HT neurons in midbrain slices
Figure 7. A, The electrical stimulation of a midline thalamic area affect-
ing the mediodorsal nucleus and a small part of the centromedial nucleus
(5 Hz, 1.5 mA, 0.3 msec pulses; shown by a bar) for 20 min increased the
5-HT release in the mPFC of chloral hydrate-anesthetized rats ( filled
triangles; n  6). Control rats were implanted with microdialysis probes
and thalamic electrodes, but no current was passed (n  6; open circles).
*p 	 0.05 versus baseline; Duncan test post-ANOVA. B, In dual probe
microdialysis experiments, the application of bicuculline (BIC; 300 M
and 1 mM, shown by a bar; n  8) by reverse dialysis in the centromedial
and mediodorsal thalamic nuclei significantly increased the 5-HT release
in mPFC. The variability of the 5-HT increase was relatively large,
possibly because of slight differences in the location of probes. *p 	 0.05
versus baseline; Duncan test post-ANOVA. C, Effects of the local appli-
cation of the glutamate uptake inhibitor L-trans-PDC, alone or in combi-
nation with NBQX, MK-801, and cyclothiazide on the 5-HT release in
4
mPFC (n  4–5). L-trans-PDC (4 mM) significantly increased the 5-HT
release. This effect was prevented by the coperfusion of NBQX but not by
MK-801 (300 M each). Cyclothiazide (300 M), a drug that prevents the
desensitization of AMPA receptors, did not affect the time course or
potentiate the effect of L-trans-PDC, suggesting that the marked tachiphy-
laxis of the effect is possibly caused by a presynaptic adaptive change in
glutamate synthesis and release resulting from prolonged inhibition of
reuptake. p 	 0.05 versus baseline; *p 	 0.05 versus L-trans-PDC alone;
Duncan test post-ANOVA.
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(Liu et al., 2000). Thus, the activation by DOI of 5-HT2A recep-
tors on GABAergic afferents to 5-HT neurons might mediate its
inhibitory effect on 5-HT neurons (Wright et al., 1990; Garratt et
al., 1991; this work) inasmuch as the activation of prefrontal
5-HT2A receptors induced the opposite effect. The involvement
of 5-HT2A and GABAA receptors in the DOI-induced inhibition
of serotonergic cell firing is supported by the reversal induced by
M100907 and picrotoxinin. Interestingly, DOI partially inhibited
the firing activity of some 5-HT neurons, whereas fully sup-
pressed other 5-HT neurons, with comparable ED50 values. This
difference suggests either a partial agonist action of DOI or the
involvement of two 5-HT2A receptor populations (e.g., in mid-
brain and mPFC) with opposed effects on the cell firing of some
neurons.
Unlike its systemic administration (Wright et al., 1990; Gobert
and Millan, 1999; this work) the local application of DOI en-
hanced the 5-HT release in mPFC. We exclude a direct releasing
action of DOI on serotonergic nerve endings (fenfluramine-like)
Figure 8. Effects of the intravenous administration of DOI on serotonergic neurons of the DR. A–E, Integrated firing rate histograms showing the effect
of DOI on five different 5-HT neurons. A–C depict neurons with full (A) and partial (B, C) inhibitory responses to the administration of cumulative doses
of DOI (25–50 g/kg, i.v. in A; 25–400 g/kg, i.v. in B, C). The effect of DOI was antagonized by M100907 (100 g/kg, i.v.; examples in B and D). The
serotonergic nature of neurons with partial or full response to DOI is illustrated by its sensitivity to 8-OH-DPAT (C, D). D shows the inhibitory effect
of DOI (25–50 g/kg, i.v.). After reversal by M100907 (100 g/kg, i.v.), 8-OH-DPAT (DPAT; 0.25–2 g/kg, i.v.) fully suppressed firing activity, and the
5-HT1A receptor antagonist WAY 100635 (WAY; 10 g/kg, i.v.) returned firing rate to baseline. E shows the reversal of the effect of DOI (25–200 g/kg,
i.v.) by the GABAA antagonist picrotoxinin (PTX; 1 mg/kg, i.v.). The graph in F shows the dose–response curves for DOI in 5-HT neurons. The neurons
with partial and full inhibitory responses to DOI administration had comparable ED50 values (19 and 22 g/kg, i.v.; n 7 and 5, respectively). The dotted
line shows the dose–response curve for all neurons (n  12).
Figure 9. Integrated firing rate histograms of DR serotonergic neurons after the application of DOI in mPFC (200 M, 200 nl, shown by a 1 min bar).
The neuron in A responded with an increase in firing rate after the first and second application of DOI (note the persistence of the increased firing rate),
whereas the neuron in B was unaffected by the application of two consecutive doses of DOI. The distal effect of DOI on 5-HT cell firing cannot be
accounted for by drug diffusion to the DR because of the small amount of tissue affected by DOI application (0.2 l) and the inhibitory effect of DOI
on 5-HT neurons when acting on DR 5-HT2A receptors (Liu et al., 2000).
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because this is insensitive to TTX (Carboni and Di Chiara, 1989).
Moreover, 5-HT neurons do not express 5-HT2A receptors (Pom-
peiano et al., 1994; Fay and Kubin, 2000) (J. Serrats, R. Corte´s, and
G. Mengod, unpublished observations). Some cells in the DR (not
known to be serotonergic) express 5-HT2C receptors (Clemett et
al., 2000). However, the lack of antagonism by SB 242084 excludes
the involvement of 5-HT2C receptors in the effect of DOI.
Several lines of evidence suggest that DOI increases the 5-HT
release in mPFC indirectly, through the stimulation of glutamate
release and subsequent activation of AMPA–KA receptors (Fig.
11). First, the 5-HT increase was reversed by NBQX but not by
MK-801 and was mimicked by AMPA application. Second, sev-
eral strategies aimed at increasing glutamatergic neurotransmis-
sion in the mPFC, such as the perfusion of the glutamate re-
uptake inhibitor L-trans-PDC (also enhancing striatal 5-HT
release; Abella´n et al., 2000) or the electrical–chemical stimula-
tion of thalamic afferents to the mPFC elevated the 5-HT release.
Third, as with DOI, the effect of L-trans-PDC was antagonized by
NBQX but not by MK-801. Finally, the effect of DOI was re-
versed by the mGluR 2/3 agonist 1S,3S-ACPD. The failure of the
more selective agonist LY 379268 to counteract the DOI-induced
5-HT increase may be attributed to different in vivo pharmaco-
logical properties and/or involvement of other mGluR subtypes
in the action of ACPD. Thus, LY 379268 increased 5-HT turn-
over and release in mPFC by itself (Cartmell et al., 2000, 2001),
an effect that would oppose the expected reduction in 5-HT
resulting from a decrease in glutamate. This difference warrants
further investigation on the mGluR subtype involved in the
control of 5-HT release in mPFC.
A critical step in the proposed mechanism is the actual assess-
ment of the effect of DOI on glutamate release. However, extra-
cellular glutamate concentrations are not representative of the
Figure 10. The systemic administration of DOI (1 mg/kg,
s.c.) markedly reduced the 5-HT output in mPFC of chloral
hydrate-anesthetized rats (n  4). The selective 5-HT2A
receptor antagonist M100907 (0.5 mg/kg, s.c.) fully re-
versed the effect of DOI. Arrows mark injections. p 	 0.05
versus baseline; *p 	 0.05 versus DOI alone; Duncan test
post-ANOVA.
Figure 11. Scheme of the putative presynaptic and postsynaptic actions of DOI. In the mPFC, DOI increases 5-HT release. This effect involves the
activation of prefrontal 5-HT2A receptors, possibly on glutamatergic afferents from midline thalamus. The role of 5-HT2A receptors on pyramidal neurons
and GABA interneurons has not been elucidated. The activation of prefrontal 5-HT2A receptors enhances the release of glutamate, which acts on
pyramidal AMPA receptors and increases impulse flow in layer V pyramidal neurons projecting to the DR, thus resulting in an increased serotonergic
activity and 5-HT release in mPFC. Additionally, glutamate might activate terminal AMPA–KA receptors in 5-HT terminals and increase 5-HT release
in a local manner. This might imply axo-axonic contacts between glutamatergic and serotonergic axons, not yet established anatomically but for which
there is functional evidence (see Discussion). The activation of inhibitory 5-HT1A receptors on pyramidal neurons counteracts the effects of DOI and
decreases 5-HT release, likely by reducing DOI excitatory effects on descending inputs to the DR, because the selective activation of prefrontal 5-HT1A
receptors reduces the firing rate of DR 5-HT neurons (Celada et al., 2001). The firing-suppressant action of systemic DOI administration on DR 5-HT
neurons is possibly accounted for by an action on local GABAergic elements inhibiting 5-HT neurons (Liu et al., 2000). This effect would also account
for the inhibition of 5-HT release observed after systemic administration of DOI.
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transmitter–synaptic pool (Timmerman and Westerink, 1997)
and depend to a large extent on a cysteine–glutamate exchanger
(Baker and Kalivas, 2000). Our own data agree with this view,
because extracellular glutamate was largely insensitive to manip-
ulations known to alter synaptic transmission (M.V. Puig, A.
Adell, P. Celada, and F. Artigas, unpublished observations).
The present results accord with previous in vitro work in mPFC
slices showing that the activation of local 5-HT2A receptors in-
creases spontaneous EPSCs in layer V pyramidal neurons by an
AMPA-dependent mechanism (Aghajanian and Marek, 1997,
1999b, 2000; Marek et al., 2000). However, none of these previous
studies reported overt depolarization in pyramidal neurons by
5-HT or DOI. In contrast, we observed that the stimulation of
5-HT2A receptors in mPFC by DOI increased the firing of iden-
tified 5-HT neurons in the DR. Likewise, in pilot experiments,
systemic DOI administration activated projection neurons in the
mPFC (Puig, Celada, and Artigas, unpublished observations).
This strongly suggests that DOI increases impulse flow in pyra-
midal neurons, including those projecting to the DR. The dis-
crepancy between the present results and those of Aghajanian
and Marek (2000) may be attributable to methodological differ-
ences, perhaps reflecting the loss of active glutamatergic inputs in
the slice preparation used by these authors.
The cellular source or sources of glutamate and the precise
localization or localizations of 5-HT2A receptors accounting for
this effect are debated. 5-HT2A receptors occur in three different
populations in frontal cortex: pyramidal neurons (major 5-HT2A-
containing neurons), GABAergic interneurons, and axon termi-
nals (Willins et al., 1997; Jakab and Goldman-Rakic, 1998, 2000;
Xu and Pandey, 2000). Layer V contains the somata of pyramidal
neurons and dense bundles of apical dendrites, highly enriched in
5-HT2A receptors (Willins et al., 1997; Jakab and Goldman-
Rakic, 1998; Xu and Pandey, 2000) (Fig. 6). GABA interneurons
are the main target of 5-HT terminals in monkey prefrontal
cortex (Smiley and Goldman-Rakic, 1996) and DOI increases
extracellular GABA in rat brain (Abi-Saab et al., 1999). However,
5-HT2A receptors on thalamic afferents have been suggested to
mediate DOI effects. Hence, -opioid agonists and lesions of the
medial thalamus attenuated the 5-HT-induced EPSCs in layer V
pyramidal neurons (Marek and Aghajanian, 1998; Marek et al.,
2001), which suggests a presynaptic site of action. Moreover, the
systemic administration of DOI increased Fos expression in su-
perficial layer V and above, an effect also dependent on the
integrity of thalamic inputs onto mPFC (Scruggs et al., 2000).
However, most Fos-expressing neurons were nonpyramidal,
whereas 5-HT induces spontaneous EPSCs in layer V pyramidal
neurons by activation of 5-HT2A receptors (Lambe et al., 2000),
which makes uncertain the relationship between both observa-
tions. The present data suggest that glutamate from thalamic
afferents to mPFC enhances 5-HT release, although it remains to
be determined whether this is the glutamate source involved in
the local DOI effects.
Indeed, a preferential action of DOI on terminal 5-HT2A
receptors would leave the dense population of pyramidal 5-HT2A
receptors without a significant role. Interestingly, the DOI-
induced increase in 5-HT release was potently counteracted by
coperfusion of the selective 5-HT1A receptor agonist BAY 
3702. 5-HT1A and 5-HT2A receptors colocalize on cortical pyra-
midal neurons (Fig. 6A–I) and have opposite effects on their
excitability (Araneda and Andrade, 1991). The apparent absence
of 5-HT1A receptors on 5-HT terminals (Pompeiano et al., 1992;
Kia et al., 1996) excludes a presynaptic action of BAY  3702.
Pyramidal neurons in mPFC project to and control the activity of
DR 5-HT neurons (see introductory remarks). Thus, DOI and
BAY  3702 may modulate the release of 5-HT in mPFC by
increasing and decreasing, respectively, the activity of descending
excitatory pathways to DR neurons projecting in turn to the
mPFC (Fig. 11). Thus, the application of DOI and 8-OH-DPAT
in mPFC increased and decreased, respectively, the firing rate of
DR 5-HT cells (Celada et al., 2001; this work). However, the
present study cannot determine whether the effect of DOI on
pyramidal activity is direct (via pyramidal 5-HT2A receptors) or
indirect (via terminal 5-HT2A receptors, increase in glutamate
and activation of AMPA receptors on pyramidal neurons) (Fig.
11). Additionally, the activation of terminal AMPA receptors
increases transmitter release in vivo and in vitro (Ohta et al., 1994;
Whitton et al., 1994; Maione et al., 1997, Tao et al., 1997; Lock-
hart et al., 2000). This raises the possibility that a second (local)
mechanism may also modulate 5-HT release independently of
DR activation.
5-HT2A receptors play a crucial role in the filtering of inputs
reaching the somata of pyramidal neurons because their activation
increases neuronal excitability. The activation by DOI of prefrontal
5-HT2A receptors increases the excitability of pyramidal neurons.
At the same time, its action on (possibly) midbrain 5-HT2A recep-
tors (Liu et al., 2000) reduces 5-HT cell firing and 5-HT release,
which should result in a diminished activation of inhibitory pyra-
midal 5-HT1A receptors. Hence, the net balance of both effects
would be an increased firing activity of projection neurons in layer
V, as preliminarily observed (Puig, Celada, and Artigas, unpub-
lished observations). This effect may mediate the hallucinogenic
action of DOI. Hence, the blockade of 5-HT2A receptors or the
direct or functional 5-HT1A receptor agonism exerted by atypical
antipsychotics (Meltzer, 1999; Ichikawa et al., 2001) might be
viewed as an attempt to restore the physiological balance between
excitatory and inhibitory inputs onto prefrontal pyramidal neurons.
Given the opposing roles of 5-HT1A and 5-HT2A receptors on the
output of layer V pyramidal neurons, compounds with 5-HT2A
antagonism and 5-HT1A agonism may be particularly useful to
treat hallucinations and, more generally, positive symptoms in
schizophrenia. Likewise, their direct action at 5-HT1A receptors
might also improve negative (deficit) symptoms.
Further work is required to clarify the relative role of local and
distal mechanisms in the control of 5-HT release by prefrontal
5-HT1A/2A receptors and the precise localization of 5-HT2A re-
ceptors responsible for this effect of DOI.
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